Edesa Biotech (EDSA) Interest & Investment Income (2013 - 2026)
Edesa Biotech (EDSA) posted Interest & Investment Income of $47.0 for Q4 2025, down 14.55% sequentially from $55.0 in Q3 2025, and down 97.18% YoY from $1666.0 in Q4 2024.
Edesa Biotech (EDSA) Interest & Investment Income (2013 - 2026) Analysis & Trends
Edesa Biotech has reported Interest & Investment Income for 13 years, with the latest figure at $47.0 in Q4 2025.
- Quarterly Interest & Investment Income fell 97.18% year-over-year to $47.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $939.0 (down 99.0% YoY) and the FY2025 annual result came in at $2558.0, down 98.33% from the prior year.
- Interest & Investment Income retreated to $47.0 in Q4 2025 per EDSA's latest filing, from $55.0 in the prior quarter.
- Over five years, Interest & Investment Income peaked at $85718.0 in Q1 2023 and troughed at $47.0 in Q4 2025.
- A 5-year average of $25985.8 and a median of $11688.5 in 2021 frame the typical range for Interest & Investment Income.
- The sharpest annual moves came in 2023 and 2025: Interest & Investment Income soared 2187.03% in 2023, then plunged 99.67% in 2025.
- Over 5 years, Interest & Investment Income stood at $6120.0 in 2021, then jumped by 707.66% to $49429.0 in 2022, then gained by 23.34% to $60966.0 in 2023, then plunged by 97.27% to $1666.0 in 2024, then plunged by 97.18% to $47.0 in 2025.
- According to Business Quant data, Interest & Investment Income over the past three periods registered $47.0, $55.0, and $572.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 28.14 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 115.94 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 10.98 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 5.13 Mn |
| 10 | Edesa Biotech | 40.44 Mn | 40.44 Mn | - | 275.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 275.00 |
| Dec 31, 2025 | 47.00 |
| Sep 30, 2025 | 55.00 |
| Jun 30, 2025 | 572.00 |
| Mar 31, 2025 | 265.00 |
| Dec 31, 2024 | 1,666.00 |
| Sep 30, 2024 | 16,491.00 |
| Jun 30, 2024 | 32,848.00 |
| Mar 31, 2024 | 43,193.00 |
| Dec 31, 2023 | 60,966.00 |
| Sep 30, 2023 | 71,945.00 |
| Jun 30, 2023 | 82,754.00 |
| Mar 31, 2023 | 85,718.00 |
| Dec 31, 2022 | 49,429.00 |
| Sep 30, 2022 | 36,137.00 |
| Jun 30, 2022 | 17,518.00 |
| Mar 31, 2022 | 3,748.00 |
| Dec 31, 2021 | 6,120.00 |
| Sep 30, 2021 | 6,886.00 |
| Jun 30, 2021 | 2,610.00 |